iCo Therapeutics (iCo Therapeutics) EV-to-EBIT : -8.30 (As of May. 05, 2024)

View and export this data going back to 2009. Start your Free Trial

What is iCo Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, iCo Therapeutics's Enterprise Value is $8.89 Mil. iCo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was $-1.07 Mil. Therefore, iCo Therapeutics's EV-to-EBIT for today is -8.30.

The historical rank and industry rank for iCo Therapeutics's EV-to-EBIT or its related term are showing as below:

ICOTF' s EV-to-EBIT Range Over the Past 10 Years
Min: -12.29 Med: -0.5 Max: 0.28
Current: -12.29

During the past 13 years, the highest EV-to-EBIT of iCo Therapeutics was 0.28. The lowest was -12.29. And the median was -0.50.

ICOTF's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 8.915 vs ICOTF: -12.29

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. iCo Therapeutics's Enterprise Value for the quarter that ended in Mar. 2021 was $280.82 Mil. iCo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 was $-1.07 Mil. iCo Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2021 was -0.38%.

iCo Therapeutics EV-to-EBIT Historical Data

The historical data trend for iCo Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iCo Therapeutics EV-to-EBIT Chart

iCo Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

EV-to-EBIT

Get a 7-Day Free Trial

-44.37

-39.37

-49.76

-126.23

-123.70

iCo Therapeutics Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
EV-to-EBIT	Get a 7-Day Free Trial															-48.11	-66.48	-87.91	-123.70	-274.43

Competitive Comparison of iCo Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, iCo Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iCo Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, iCo Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where iCo Therapeutics's EV-to-EBIT falls into.

iCo Therapeutics EV-to-EBIT Calculation

iCo Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	8.893	/	-1.072
	=	-8.30

iCo Therapeutics's current Enterprise Value is $8.89 Mil.
iCo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.07 Mil.

iCo Therapeutics (GREY:ICOTF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

iCo Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2021 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2021 )	=	EBIT	/	Enterprise Value (Q: Mar. 2021 )
	=	-1.072	/	280.81648
	=	-0.38 %

iCo Therapeutics's Enterprise Value for the quarter that ended in Mar. 2021 was $280.82 Mil.
iCo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.07 Mil.

iCo Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of iCo Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

iCo Therapeutics (iCo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » iCo Therapeutics Inc (GREY:ICOTF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

777 Hornby Street, 6th Floor, Vancouver, BC, CAN, V6Z 1S4

Website

http://www.icotherapeutics.com

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between the cells of the immune system. Geographically, it operates in Canada and Australia.

iCo Therapeutics (iCo Therapeutics) Headlines

No Headlines